Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dopamine agonist-responsive Cushing's disease.

Gurpreet Anand1, Andrea Bink2, Felix Beuschlein1

  • 1Department of Endocrinology, University Hospital Zürich, Zürich, Switzerland.

BMJ Case Reports
|February 16, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postsurgical detection of glioma recurrence using MRI radiomics.

Neuro-oncology advances·2026
Same author

Treatment of Leukemic Blood Samples with Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Is Associated with Reduced Frequencies of Tolerogenic Dendritic Cells and Increased Cytotoxicity Against Autologous Blasts.

Biomedicines·2026
Same author

Prediction of treatment failure in patients with glioblastoma with perfusion MRI and molecular biomarkers.

Neuro-oncology advances·2026
Same author

Transition from In-Person to Online Boards-An Exploratory Pilot Study on Pituitary Tumor Board Meetings.

Journal of clinical medicine·2026
Same author

Modulation of Leukemic Blasts into Dendritic Cells (DC<sub>leu</sub>) and Their Role in Predicting Survival in Patients with AML and MDS.

Cancers·2026
Same author

Three-Dimensional quantitative analysis of the Peri-Enhancing zone reveals ADC and CBV signatures of glioblastoma recurrence.

NeuroImage. Clinical·2026
Same journal

Canaliculitis associated with multiple retained silicone punctal plugs and concurrent biodegradable plug placement.

BMJ case reports·2026
Same journal

Bilateral vocal cord paralysis in multifocal motor neuropathy.

BMJ case reports·2026
Same journal

Multiple visceral artery aneurysms and type II Abernethy malformation in a patient with autoimmune hepatitis.

BMJ case reports·2026
Same journal

Congenital nasolacrimal duct cyst complicating as an orbital abscess.

BMJ case reports·2026
Same journal

Management of <i>Achromobacter xylosoxidans</i> bacteraemia with an atypical antimicrobial resistance pattern.

BMJ case reports·2026
Same journal

Unintentional chronic acetaminophen overuse as an under-recognised cause of liver injury.

BMJ case reports·2026
See all related articles

A pituitary tumor caused Cushing's syndrome, high prolactin, and other hormonal issues. Dopamine agonist treatment successfully resolved these conditions and reduced tumor size.

Area of Science:

  • Endocrinology
  • Neuroendocrinology
  • Oncology

Background:

  • Investigating a patient with severe endogenous hypercortisolism.
  • Assessing complex hormonal imbalances including hyperprolactinemia, elevated growth hormone, hypogonadotropic hypogonadism, and central hypothyroidism.

Observation:

  • A 47-year-old man presented with symptoms of Cushing's syndrome and additional endocrine dysfunctions.
  • Diagnostic workup revealed an invasive pituitary macroadenoma as the underlying cause.

Findings:

  • The pituitary macroadenoma was confirmed to be secreting adrenocorticotropic hormone (ACTH), prolactin, and growth hormone.
  • The patient experienced a remarkable response to dopamine agonist therapy, achieving remission of Cushing's syndrome and normalization of prolactin levels.
Keywords:
endocrine systempituitary disorders

Related Experiment Videos

  • Tumor size significantly decreased on follow-up magnetic resonance imaging (MRI) scans.

    • Implications:

    • This case highlights the potential for plurihormonal pituitary adenomas to cause complex clinical presentations.
    • Dopamine agonist therapy can be an effective treatment for specific types of pituitary macroadenomas, even those with mixed hormone secretion.
    • Successful management of such tumors can lead to significant clinical improvement and tumor regression.